English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A 59-year-old man was admitted to our hospital with a left renal mass. A tumor was removed by radical nephrectomy and histological examination revealed renal cell carcinoma (pT2 N0 V1a). Two years later, CT scan showed multiple lung metastases. Despite treatment with recombinant IFN-alpha 2b, 5-FU, and MMC, the disease showed slow progression. About three years after the start of combination therapy, cervical lymph node metastasis appeared. Administration of interleukin-2 (IL-2) was attempted. Intravenous IL-2 therapy was started at a low daily dose of 35 x 10(4) JRU, and the daily dose was increased to 140 x 10(4) JRU. Because of side effect, the dose was subsequently decreased to 70 x 10(4) JRU three times per week. After 31 weeks of IL-2 therapy, his multiple lung metastases and cervical lymph node metastasis disappeared. The patient's natural killer cell (NK) activity and Lymphokine activated killer cell (LAK) activity were low before IL-2 therapy, but both NK activity and LAK activity showed a marked increase after IL-2 therapy started. Therefore, the tumor response to IL-2 was suggested to depend on NK activity and LAK activity.

nihon hinyoukika gakkai zasshi/nippon hinyokika gakkai zasshi

A CASE OF MULIPLELUNG METASTASES AND CERVICAL LYMPH NODE METASTASIS OF RENAL CELL CARCINOMA FAILING TO RESPOND TO INTERFERON-^|^alpha; (IFN-^|^alpha;) BUT MARKEDLY RESPONDING TO INTERLEUKIN-2 (IL-2)